113 related articles for article (PubMed ID: 25535658)
1. Quantitative computed tomographic assessment of bone mineral density changes associated with administration of prednisolone or prednisolone and alendronate sodium in dogs.
Park S; Oh J; Son KY; Cho KO; Choi J
Am J Vet Res; 2015 Jan; 76(1):28-34. PubMed ID: 25535658
[TBL] [Abstract][Full Text] [Related]
2. Alendronate improves low bone mineral density induced by steroid therapy in Crohn's disease.
Tsujikawa T; Andoh A; Inatomi O; Bamba S; Nakahara T; Sasaki M; Saito H; Fujiyama Y
Intern Med; 2009; 48(12):933-7. PubMed ID: 19525577
[TBL] [Abstract][Full Text] [Related]
3. Effect of alendronate on bone metabolic indices and bone mineral density in patients treated with high-dose glucocorticoid: a prospective study.
Kaji H; Kuroki Y; Murakawa Y; Funakawa I; Funasaka Y; Kanda F; Sugimoto T
Osteoporos Int; 2010 Sep; 21(9):1565-71. PubMed ID: 19921083
[TBL] [Abstract][Full Text] [Related]
4. Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study.
Tee SI; Yosipovitch G; Chan YC; Chua SH; Koh ET; Chan YH; Tan SS; Tsou IY; Tan SH
Arch Dermatol; 2012 Mar; 148(3):307-14. PubMed ID: 22105813
[TBL] [Abstract][Full Text] [Related]
5. Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis.
Devogelaer JP; Adler RA; Recknor C; See K; Warner MR; Wong M; Krohn K
J Rheumatol; 2010 Jan; 37(1):141-8. PubMed ID: 19918047
[TBL] [Abstract][Full Text] [Related]
6. Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients: a retrospective, observational study.
Emkey R; Delmas PD; Goemaere S; Liberman UA; Poubelle PE; Daifotis AG; Verbruggen N; Lombardi A; Czachur M
Arthritis Rheum; 2003 Apr; 48(4):1102-8. PubMed ID: 12687554
[TBL] [Abstract][Full Text] [Related]
7. Prevention of corticosteroid-induced bone loss with alendronate.
Wimalawansa SJ; Simmons DJ
Proc Soc Exp Biol Med; 1998 Feb; 217(2):162-7. PubMed ID: 9452139
[TBL] [Abstract][Full Text] [Related]
8. Effects of alendronate or alfacalcidol on bone metabolic indices and bone mineral density in patients with ophthalmologic disease treated with glucocorticoid.
Ikeda T; Maruyama K; Kaji H; Akagi M
Mod Rheumatol; 2014 Jul; 24(4):671-6. PubMed ID: 24313921
[TBL] [Abstract][Full Text] [Related]
9. Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy.
Okada Y; Nawata M; Nakayamada S; Saito K; Tanaka Y
J Rheumatol; 2008 Nov; 35(11):2249-54. PubMed ID: 19031508
[TBL] [Abstract][Full Text] [Related]
10. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
Lems WF; Lodder MC; Lips P; Bijlsma JW; Geusens P; Schrameijer N; van de Ven CM; Dijkmans BA
Osteoporos Int; 2006; 17(5):716-23. PubMed ID: 16463007
[TBL] [Abstract][Full Text] [Related]
11. Density and structural changes in the bone of growing rats after weekly alendronate administration with and without a methotrexate challenge.
Spadaro JA; Damron TA; Horton JA; Margulies BS; Murray GM; Clemente DA; Strauss JA
J Orthop Res; 2006 May; 24(5):936-44. PubMed ID: 16609966
[TBL] [Abstract][Full Text] [Related]
12. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
Klotz LH; McNeill IY; Kebabdjian M; Zhang L; Chin JL;
Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
[TBL] [Abstract][Full Text] [Related]
13. Effects of alendronate on bone metabolism in glucocorticoid-induced osteoporosis measured by 18F-fluoride PET: a prospective study.
Uchida K; Nakajima H; Miyazaki T; Yayama T; Kawahara H; Kobayashi S; Tsuchida T; Okazawa H; Fujibayashi Y; Baba H
J Nucl Med; 2009 Nov; 50(11):1808-14. PubMed ID: 19837766
[TBL] [Abstract][Full Text] [Related]
14. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
15. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
Saag KG; Shane E; Boonen S; MarĂn F; Donley DW; Taylor KA; Dalsky GP; Marcus R
N Engl J Med; 2007 Nov; 357(20):2028-39. PubMed ID: 18003959
[TBL] [Abstract][Full Text] [Related]
16. [Alendronate prevents steroid-induced osteoporosis in patients with rheumatic diseases].
Wang QH; Wu HX; Huang YL; Xue J; Yang XY; Zhu L; Wen LH
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(27):1888-91. PubMed ID: 19040000
[TBL] [Abstract][Full Text] [Related]
17. Effect of alendronate on glucocorticoid-induced osteoporosis in Japanese women with systemic autoimmune diseases: versus alfacalcidol.
Takeda S; Kaneoka H; Saito T
Mod Rheumatol; 2008; 18(3):271-6. PubMed ID: 18427724
[TBL] [Abstract][Full Text] [Related]
18. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
Stoch SA; Saag KG; Greenwald M; Sebba AI; Cohen S; Verbruggen N; Giezek H; West J; Schnitzer TJ
J Rheumatol; 2009 Aug; 36(8):1705-14. PubMed ID: 19487264
[TBL] [Abstract][Full Text] [Related]
19. Bone quality in zebrafish vertebrae improves after alendronate administration in a glucocorticoid-induced osteoporosis model.
Bohns FR; Akhtar R; Chuang YJ; Chen PY
J Mech Behav Biomed Mater; 2024 Jun; 154():106521. PubMed ID: 38555661
[TBL] [Abstract][Full Text] [Related]
20. Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis.
Jacobs JW; de Nijs RN; Lems WF; Geusens PP; Laan RF; Huisman AM; Algra A; Buskens E; Hofbauer LC; Oostveen AC; Bruyn GA; Dijkmans BA; Bijlsma JW
J Rheumatol; 2007 May; 34(5):1051-7. PubMed ID: 17407214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]